The Role of Genetic Variation in the Lamin A/c Gene in the Etiology of Polycystic Ovary Syndrome

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2009 Apr 30

PMID 19401371

Citations 4

Authors

Margrit Urbanek

Geetha Nampiaparampil

Janine DSouza

Elizabeth Sefton

Christine Ackerman

Richard S Legro

Andrea Dunaif

Affiliations

Soon will be listed here.

Abstract

Objective: We performed this study to test the hypothesis that variation in the lamin a/c gene (LMNA) contributes to milder phenotypes of insulin resistance, hyperandrogenism, and/or metabolic syndrome associated with polycystic ovary syndrome (PCOS).

Research Design And Methods: We resequenced the coding region, flanking intronic, and proximal promoter regions of the lamin a/c gene in 43 women with PCOS with evidence of upper-body obesity (waist circumference >88 cm) and identified 56 variants, two of which were nonsynonymous substitutions (lmna11 exon1 E98D; lmna24 exon 7 R455C). We genotyped 53 single-nucleotide polymorphisms (44 identified through resequencing and nine included to maximize informativeness of the entire gene) in 624 index (PCOS) cases and 544 controls of European ancestry. We tested for association between these variants and PCOS. In a subset of individuals, we also tested for association with metabolic syndrome and quantitative traits (body mass index, waist circumference, total testosterone, dehydroepiandrosterone sulfate, fasting glucose and insulin, low-density lipoprotein, and total triglycerides).

Results: After correction for multiple testing, none of the variants showed significant evidence for association with PCOS, the metabolic syndrome, or any of the quantitative traits tested.

Conclusions: Whereas these studies cannot exclude the role of genetic variation in the lamin a/c gene in isolated cases of PCOS, we can conclude that common variation in the lamin a/c gene does not contribute to the etiology of PCOS in women of European ancestry.

Citing Articles

Review of Mendelian Randomization Studies on Endometrial Cancer.

Guo J, Wu Q, Liu F, Gao C, Gong T, Li G Front Endocrinol (Lausanne). 2022; 13:783150.

PMID: 35615721 PMC: 9124776. DOI: 10.3389/fendo.2022.783150.

Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.

Liu Y, Sun M, Jiang R, Ding R, Che Z, Chen Y J Assist Reprod Genet. 2014; 31(3):363-70.

PMID: 24435452 PMC: 3947070. DOI: 10.1007/s10815-013-0171-2.

Evaluating reported candidate gene associations with polycystic ovary syndrome.

Pau C, Saxena R, Welt C Fertil Steril. 2013; 99(6):1774-8.

PMID: 23375202 PMC: 3722586. DOI: 10.1016/j.fertnstert.2012.12.033.

Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases.

Zhavoronkov A, Smit-McBride Z, Guinan K, Litovchenko M, Moskalev A J Mol Med (Berl). 2012; 90(12):1361-89.

PMID: 23090008 PMC: 3506837. DOI: 10.1007/s00109-012-0962-4.

References

Urbanek M, Legro R, Driscoll D, Azziz R, Ehrmann D, Norman R . Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999; 96(15):8573-8. PMC: 17558. DOI: 10.1073/pnas.96.15.8573. View

Sam S, Legro R, Bentley-Lewis R, Dunaif A . Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(8):4797-802. PMC: 4428585. DOI: 10.1210/jc.2004-2217. View

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; 19(1):41-7. DOI: 10.1093/humrep/deh098. View

Agarwal A, Garg A . Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med. 2006; 57:297-311. DOI: 10.1146/annurev.med.57.022605.114424. View

Urbanek M, Sam S, Legro R, Dunaif A . Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab. 2007; 92(11):4191-8. DOI: 10.1210/jc.2007-0761. View

Gambineri A, Semple R, Forlani G, Genghini S, Grassi I, Hyden C . Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol. 2008; 159(3):347-53. DOI: 10.1530/EJE-08-0272. View

Monajemi H, Stroes E, Hegele R, Fliers E . Inherited lipodystrophies and the metabolic syndrome. Clin Endocrinol (Oxf). 2007; 67(4):479-84. DOI: 10.1111/j.1365-2265.2007.02906.x. View

Worman H, Bonne G . "Laminopathies": a wide spectrum of human diseases. Exp Cell Res. 2007; 313(10):2121-33. PMC: 2964355. DOI: 10.1016/j.yexcr.2007.03.028. View

Young J, Morbois-Trabut L, Couzinet B, Lascols O, Dion E, Bereziat V . Type A insulin resistance syndrome revealing a novel lamin A mutation. Diabetes. 2005; 54(6):1873-8. DOI: 10.2337/diabetes.54.6.1873. View

10.

Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17):2735-52. DOI: 10.1161/CIRCULATIONAHA.105.169404. View

11.

Altshuler D, Hirschhorn J, Klannemark M, Lindgren C, Vohl M, Nemesh J . The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000; 26(1):76-80. DOI: 10.1038/79216. View

12.

Hegele R, Cao H, Frankowski C, Mathews S, Leff T . PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002; 51(12):3586-90. DOI: 10.2337/diabetes.51.12.3586. View

13.

Decaudain A, Vantyghem M, Guerci B, Hecart A, Auclair M, Reznik Y . New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J Clin Endocrinol Metab. 2007; 92(12):4835-44. DOI: 10.1210/jc.2007-0654. View

14.

Antoine H, Pall M, Trader B, Chen Y, Azziz R, Goodarzi M . Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril. 2006; 87(4):862-9. PMC: 1925257. DOI: 10.1016/j.fertnstert.2006.10.006. View

15.

Legro R, Finegood D, Dunaif A . A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998; 83(8):2694-8. DOI: 10.1210/jcem.83.8.5054. View

16.

Sam S, Dunaif A . Polycystic ovary syndrome: syndrome XX?. Trends Endocrinol Metab. 2003; 14(8):365-70. DOI: 10.1016/j.tem.2003.08.002. View

17.

Sam S, Legro R, Essah P, Apridonidze T, Dunaif A . Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A. 2006; 103(18):7030-5. PMC: 1459013. DOI: 10.1073/pnas.0602025103. View

18.

Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B . The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2005; 62(5):573-9. DOI: 10.1111/j.1365-2265.2005.02261.x. View

19.

Skol A, Scott L, Abecasis G, Boehnke M . Optimal designs for two-stage genome-wide association studies. Genet Epidemiol. 2007; 31(7):776-88. DOI: 10.1002/gepi.20240. View

20.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11):4237-45. DOI: 10.1210/jc.2006-0178. View